{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:49:19Z","timestamp":1791521359694,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the recurrence rate of neovascular activity after discontinuation of intravitreal anti\u2013vascular endothelial growth factor (VEGF) therapy in patients with neovascular age-related macular degeneration (AMD) and to identify baseline clinical and imaging factors associated with relapse following a clinical exit strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, patients with neovascular AMD who discontinued anti-VEGF therapy due to a clinical decision were identified. Treatment discontinuation was based on the absence of foveal exudation on optical coherence tomography (OCT). Baseline demographic, clinical, and OCT characteristics were analyzed. The primary outcome was disease recurrence, defined as the need for a new intravitreal anti-VEGF injection during follow-up. Multivariate regression analysis was performed to identify baseline biomarkers associated with relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-eight patients (78 eyes) were included (mean age 82.3\u2009\u00b1\u20095.5 years; 78.2% women). Disease recurrence occurred in 38 patients (48.7%) after a mean of 389.0\u2009\u00b1\u2009247.3 days, with 47.4% of relapses occurring within the first year. Visual acuity significantly worsened between treatment discontinuation and relapse (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At the time of retreatment, intraretinal fluid, subretinal fluid, and subretinal hyperreflective material were observed in 57.9%, 63.2%, and 55.3% of eyes, respectively. Multivariate regression identified extrafoveal intraretinal fluid and retinal pigment epithelium tear at baseline as biomarkers associated with recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recurrence after anti-VEGF discontinuation is common in neovascular AMD. The presence of extrafoveal intraretinal fluid and retinal pigment epithelium tear at treatment cessation may increase the risk of relapse, highlighting the need for cautious treatment exit strategies and close post-discontinuation monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07560-2","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:55:57Z","timestamp":1791514557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical exit strategy in anti-VEGF therapy for neovascular AMD: incidence of recurrence and risk factors for relapse"],"prefix":"10.1007","author":[{"given":"Claudio","family":"Foti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Ulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Trastu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Avitabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza Maria Elena","family":"Bonfiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"7560_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.4.564","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS (2004) Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol 122:564","journal-title":"Arch Ophthalmol"},{"key":"7560_CR2","first-page":"147","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024) Age-Related Macular Degeneration JAMA 331:147","journal-title":"Age-Related Macular Degeneration JAMA"},{"key":"7560_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris","year":"2013","unstructured":"Ferris FL, Wilkinson CP, Bird A et al (2013) Clinical Classification of Age-related Macular Degeneration. Ophthalmology 120:844\u2013851","journal-title":"Ophthalmology"},{"key":"7560_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology 116:57\u201365e5","journal-title":"Ophthalmology"},{"key":"7560_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"7560_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"7560_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"7560_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS et al (2024) Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152","journal-title":"Lancet"},{"key":"7560_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA LUCERNE Ophthalmol 131:914\u2013926","journal-title":"TENAYA LUCERNE Ophthalmol"},{"key":"7560_CR10","doi-asserted-by":"crossref","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. ;127:72\u201384","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"7560_CR11","doi-asserted-by":"crossref","unstructured":"Li E, Donati S, Lindsley KB et al (2020) Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. ;2020","DOI":"10.1002\/14651858.CD012208.pub2"},{"key":"7560_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/jcm11020325","volume":"11","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Soppelsa V et al (2022) Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression. J Clin Med 11:325","journal-title":"J Clin Med"},{"key":"7560_CR13","doi-asserted-by":"crossref","unstructured":"Borrelli E, Boscia F, Lanzetta P et al (2025) Intravitreal faricimab for diabetic macular oedema and neovascular age-related macular degeneration: general considerations and practical recommendations by an expert panel of Italian retina specialists. Eye","DOI":"10.1038\/s41433-025-03997-7"},{"key":"7560_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1167\/iovs.66.9.55","volume":"66","author":"G Neri","year":"2025","unstructured":"Neri G, Rebecchi C, Oakley JD et al (2025) Deep Learning Model for Automated Classification of Macular Neovascularization Subtypes in AMD. Invest Ophthalmol Vis Sci 66:55","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7560_CR15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/bjo-2023-324647","volume":"108","author":"F Ricardi","year":"2024","unstructured":"Ricardi F, Oakley J, Russakoff D et al (2024) Validation of a deep learning model for automatic detection and quantification of five OCT critical retinal features associated with neovascular age-related macular degeneration. Br J Ophthalmol 108:1436\u20131442","journal-title":"Br J Ophthalmol"},{"key":"7560_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2024.08.024","volume":"269","author":"A BERNI","year":"2025","unstructured":"BERNI A, OAKLEY JD, DOLZ-MARCO R et al (2025) Topographical Quantification of Retinal Fluid in Type 3 MNV and Associations With Short-Term Visual Outcomes. Am J Ophthalmol 269:181\u2013188","journal-title":"Am J Ophthalmol"},{"key":"7560_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/bjo-2024-326152","volume":"109","author":"E Borrelli","year":"2025","unstructured":"Borrelli E, Foti C, Ulla L et al (2025) Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration. Br J Ophthalmol 109:875\u2013881","journal-title":"Br J Ophthalmol"},{"key":"7560_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2022","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D (2022) Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen. Ophthalmol Retina 6:15\u201320","journal-title":"Ophthalmol Retina"},{"key":"7560_CR19","doi-asserted-by":"crossref","unstructured":"Coletto A, Serafino S, Olivieri C, et al (2025) Macular fibrosis in neovascular AMD: inter-reader and intermodality variability across four imaging modalities. Can J Ophthalmol 60(6):e906\u2013e914","DOI":"10.1016\/j.jcjo.2025.05.019"},{"key":"7560_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2023.07.022","volume":"256","author":"KC Awh","year":"2023","unstructured":"Awh KC, Mahmoudzadeh R, Salabati M et al (2023) Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration. Am J Ophthalmol 256:20\u201326","journal-title":"Am J Ophthalmol"},{"key":"7560_CR21","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1167\/iovs.11-8755","volume":"53","author":"Y Huang","year":"2012","unstructured":"Huang Y, Gangaputra S, Lee KE et al (2012) Signal Quality Assessment of Retinal Optical Coherence Tomography Images. Invest Opthalmology Visual Sci 53:2133","journal-title":"Invest Opthalmology Visual Sci"},{"key":"7560_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41598-022-27078-x","volume":"13","author":"A Selvam","year":"2023","unstructured":"Selvam A, Singh SR, Arora S et al (2023) Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration. Sci Rep 13:68","journal-title":"Sci Rep"},{"key":"7560_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/iovs.63.11.4","volume":"63","author":"H Fukuyama","year":"2022","unstructured":"Fukuyama H, Huang BB, BouGhanem G, Fawzi AA (2022) The Fovea-Protective Impact of Double-Layer Sign in Eyes With Foveal-Sparing Geographic Atrophy and Age-Related Macular Degeneration. Invest Opthalmology Visual Sci 63:4","journal-title":"Invest Opthalmology Visual Sci"},{"key":"7560_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.oret.2023.10.006","volume":"8","author":"L Csincsik","year":"2024","unstructured":"Csincsik L, Muldrew KA, Bettiol A et al (2024) The Double Layer Sign Is Highly Predictive of Progression to Exudation in Age-Related Macular Degeneration. Ophthalmol Retina 8:234\u2013245","journal-title":"Ophthalmol Retina"},{"key":"7560_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.oret.2018.10.012","volume":"3","author":"Y Shi","year":"2019","unstructured":"Shi Y, Motulsky EH, Goldhardt R et al (2019) Predictive Value of the OCT Double-Layer Sign for Identifying Subclinical Neovascularization in Age-Related Macular Degeneration. Ophthalmol Retina 3:211\u2013219","journal-title":"Ophthalmol Retina"},{"key":"7560_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ajo.2016.06.031","volume":"169","author":"KK Dansingani","year":"2016","unstructured":"Dansingani KK, Tan ACS, Gilani F et al (2016) Subretinal Hyperreflective Material Imaged With Optical Coherence Tomography Angiography. Am J Ophthalmol 169:235\u2013248","journal-title":"Am J Ophthalmol"},{"key":"7560_CR27","doi-asserted-by":"publisher","first-page":"100280","DOI":"10.1016\/j.xops.2023.100280","volume":"3","author":"A Berlin","year":"2023","unstructured":"Berlin A, Cabral D, Chen L et al (2023) Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration. Ophthalmol Sci 3:100280","journal-title":"Ophthalmol Sci"},{"key":"7560_CR28","doi-asserted-by":"crossref","unstructured":"Berni A, Foti C, Bandello F et al (2025) Predictors of Macular Atrophy after Serous Pigment Epithelial Detachment Collapse in Type 3 Macular Neovascularization and Age-Related Macular Degeneration. Ophthalmol Retina","DOI":"10.1016\/j.oret.2025.05.028"},{"key":"7560_CR29","first-page":"990","volume":"60","author":"E Borrelli","year":"2024","unstructured":"Borrelli E, Serafino S, Ricardi F et al (2024) Deep Learning in Neovascular Age-Related Macular Degeneration. Med (B Aires) 60:990","journal-title":"Med (B Aires)"},{"key":"7560_CR30","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying G, Toth CA et al (2015) Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 122:1846\u20131853e5","journal-title":"Ophthalmology"},{"key":"7560_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3928\/23258160-20150521-03","volume":"46","author":"W Charafeddin","year":"2015","unstructured":"Charafeddin W, Nittala MG, Oregon A, Sadda SR (2015) Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmic Surg Lasers Imaging Retina 46:523\u2013530","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"7560_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/11206721241265998","volume":"35","author":"E Borrelli","year":"2025","unstructured":"Borrelli E, Boscia G, Gelormini F et al (2025) Macular thickness and visual acuity are characterized by a quadratic nonlinear relation in previously treated neovascular AMD eyes. Eur J Ophthalmol 35:650\u2013659","journal-title":"Eur J Ophthalmol"},{"key":"7560_CR33","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/s41598-022-19062-2","volume":"12","author":"Y Hirata","year":"2022","unstructured":"Hirata Y, Oishi A, Maekawa Y et al (2022) Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen. Sci Rep 12:14768","journal-title":"Sci Rep"},{"key":"7560_CR34","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.3390\/jcm13154317","volume":"13","author":"S Chujo","year":"2024","unstructured":"Chujo S, Matsubara H, Mase Y et al (2024) Recurrence Rate during 5-Year Period after Suspension of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. J Clin Med 13:4317","journal-title":"J Clin Med"},{"key":"7560_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2022","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D (2022) Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen. Ophthalmol Retina 6:15\u201320","journal-title":"Ophthalmol Retina"},{"key":"7560_CR36","doi-asserted-by":"crossref","unstructured":"Jaggi D, Marugg S, Berger LE et al (2026) Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit. Br J Ophthalmol 110(4):440\u2013445","DOI":"10.1136\/bjo-2025-327721"},{"key":"7560_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/IAE.0000000000001576","volume":"37","author":"Y Ichiyama","year":"2017","unstructured":"Ichiyama Y, Sawada T, Ito Y, OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS BLOOD FLOW IN CHOROIDAL NEOVASCULAR MEMBRANE IN REMISSION PHASE OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION et al (2017) Retina 37:724\u2013730","journal-title":"Retina"},{"key":"7560_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4806061","volume":"2019","author":"M Stattin","year":"2019","unstructured":"Stattin M, Forster J, Daniel A et al (2019) Relationship between Neovascular Density in Swept Source-Optical Coherence Tomography Angiography and Signs of Activity in Exudative Age-Related Macular Degeneration. J Ophthalmol 2019:1\u20138","journal-title":"J Ophthalmol"},{"key":"7560_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2022","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D (2022) Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen. Ophthalmol Retina 6:15\u201320","journal-title":"Ophthalmol Retina"},{"key":"7560_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","volume":"6","author":"S Riedl","year":"2022","unstructured":"Riedl S, Vogl W-D, Waldstein SM et al (2022) Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial. Ophthalmol Retina 6:291\u2013297","journal-title":"Ophthalmol Retina"},{"key":"7560_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"42","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW (2022) IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 42:589\u2013606","journal-title":"Retina"},{"key":"7560_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2021.06.029","volume":"233","author":"NM Holekamp","year":"2022","unstructured":"Holekamp NM, Sadda S, Sarraf D et al (2022) Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration. Am J Ophthalmol 233:8\u201317","journal-title":"Am J Ophthalmol"},{"key":"7560_CR43","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E et al (2016) Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123:865\u2013875","journal-title":"Ophthalmology"},{"key":"7560_CR44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/IAE.0000000000000902","volume":"36","author":"SS Wickremasinghe","year":"2016","unstructured":"Wickremasinghe SS, Janakan V, Sandhu SS, IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED et al (2016) MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL. Retina 36:1331\u20131339","journal-title":"Retina"},{"key":"7560_CR45","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G et al (2016) Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. Ophthalmology 123:1521\u20131529","journal-title":"Ophthalmology"},{"key":"7560_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying G-S, Toth CA et al (2019) Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 126:252\u2013260","journal-title":"Ophthalmology"},{"key":"7560_CR47","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe GJ, Martin DF, Toth CA et al (2013) Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 120:1860\u20131870","journal-title":"Ophthalmology"},{"key":"7560_CR48","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl W-D, Jampol LM, Bogunovi\u0107 H (2020) Application of Automated Quantification of Fluid Volumes to Anti\u2013VEGF Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology 127:1211\u20131219","journal-title":"Ophthalmology"},{"key":"7560_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.oret.2017.03.015","volume":"2","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Bogunovic H, Sadeghipour A et al (2018) Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmol Retina 2:24\u201330","journal-title":"Ophthalmol Retina"},{"key":"7560_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/IAE.0b013e3180a032db","volume":"27","author":"CHANG LK","year":"2007","unstructured":"CHANG LK (2007) TEARS OF THE RETINAL PIGMENT EPITHELIUM. Retina 27:523\u2013534","journal-title":"Retina"},{"key":"7560_CR51","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1097\/IAE.0000000000001062","volume":"36","author":"A Mouallem","year":"2016","unstructured":"Mouallem A, Sarraf D, Chen X et al (2016) DOUBLE RETINAL PIGMENT EPITHELIUM TEARS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 36:2197\u20132204","journal-title":"Retina"},{"key":"7560_CR52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.survophthal.2017.03.004","volume":"62","author":"MG Ersoz","year":"2017","unstructured":"Ersoz MG, Karacorlu M, Arf S et al (2017) Retinal pigment epithelium tears: Classification, pathogenesis, predictors, and management. Surv Ophthalmol 62:493\u2013505","journal-title":"Surv Ophthalmol"},{"key":"7560_CR53","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/IAE.0b013e3180342c42","volume":"27","author":"CJ CHANG LK, FLAXEL","year":"2007","unstructured":"CHANG LK, FLAXEL CJ, LAUER AK (2007) RPE TEARS AFTER PEGAPTANIB TREATMENT IN AGE-RELATED MACULAR DEGENERATION. Retina 27:857\u2013863","journal-title":"Retina"},{"key":"7560_CR54","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/IAE.0b013e3181cdf366","volume":"30","author":"D Sarraf","year":"2010","unstructured":"Sarraf D, Reddy S, Chiang A et al (2010) A NEW GRADING SYSTEM FOR RETINAL PIGMENT EPITHELIAL TEARS. Retina 30:1039\u20131045","journal-title":"Retina"},{"key":"7560_CR55","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/IAE.0b013e31828992f5","volume":"33","author":"D Sarraf","year":"2013","unstructured":"Sarraf D, Chan C, Rahimy E, Abraham P, PROSPECTIVE EVALUATION OF, THE INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY (2013) Retina 33:1551\u20131557","journal-title":"Retina"},{"key":"7560_CR56","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"123","author":"D Sarraf","year":"2016","unstructured":"Sarraf D, London NJS, Khurana RN et al (2016) Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. Ophthalmology 123:2213\u20132224","journal-title":"Ophthalmology"},{"key":"7560_CR57","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ajo.2013.06.024","volume":"156","author":"A Nagiel","year":"2013","unstructured":"Nagiel A, Freund KB, Spaide RF et al (2013) Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography. Am J Ophthalmol 156:981\u2013988e2","journal-title":"Am J Ophthalmol"},{"key":"7560_CR58","first-page":"142","volume":"112","author":"D Sarraf","year":"2014","unstructured":"Sarraf D, Joseph A, Rahimy E (2014) Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 112:142\u2013159","journal-title":"Trans Am Ophthalmol Soc"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07560-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07560-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07560-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:02:16Z","timestamp":1791518536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07560-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":58,"alternative-id":["7560"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07560-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}